Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer

Phase 2

Conditions: Platinum-resistant Recurrent Ovarian Cancer

Interventions: Drug: PLD 40mg/m2 ivgtt q4w
Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd

First Posted Date: 2020-04-15

Last Posted Date: 2022-03-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 152

Registration Number: NCT04348032

Locations: 🇨🇳
National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Hubei Cancer Hospital, Hubei, Hubei, China

and more 13 locations

Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients

Phase 3

Conditions: Breast Cancer

Interventions: Radiation: internal mammary nodal irradiation
Radiation: no internal mammary nodal irradiation

First Posted Date: 2020-03-25

Last Posted Date: 2022-01-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 2000

Registration Number: NCT04320979

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Conditions: EGFR Mutation-Related Tumors
Stage III Non-small-cell Lung Cancer
Non Small Cell Lung Cancer

Interventions: Radiation: radiation or chemo-radiation
Drug: EGFR-TKI Inhibitor

First Posted Date: 2020-03-11

Last Posted Date: 2020-03-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 450

Registration Number: NCT04304638

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Conditions: Breast Cancer

Interventions: Drug: Palbociclib

First Posted Date: 2020-02-28

Last Posted Date: 2020-02-28

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT04289974

Locations: 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China

Chemoradiotherapy in Unresectable Esophageal Cancer

Phase 1

Recruiting

Conditions: Chemoradiotherapy
Albumin-bound Paxlitaxel
Esophageal Cancer
Unresectable Malignant Neoplasm

Interventions: Radiation: Radiotherapy
Drug: Albumin-Bound Paclitaxel
Drug: Cisplatin

First Posted Date: 2020-02-20

Last Posted Date: 2024-12-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 105

Registration Number: NCT04278287

Locations: 🇨🇳
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
🇨🇳
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

and more 2 locations

Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Procedure: Intensity modulated radiotherapy (IMRT)
Drug: Chemotherapy

First Posted Date: 2020-02-19

Last Posted Date: 2021-07-07

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 56

Registration Number: NCT04275986

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Biological: Bevacizumab
Drug: Capecitabine
Drug: Irinotecan
Drug: 5-FU
Drug: CF

First Posted Date: 2020-01-30

Last Posted Date: 2022-03-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 264

Registration Number: NCT04247984

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

Purified Inactivated Japanese Encephalitis Vaccine

Phase 3

Conditions: Japanese Encephalitis Virus Disease

Interventions: Biological: Japanese Encephalitis Vaccine produced by IMBCAMS
Biological: Japanese Encephalitis Vaccine produced by Liaoning Chenda

First Posted Date: 2020-01-10

Last Posted Date: 2022-03-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 1050

Registration Number: NCT04223037

Locations: 🇨🇳
Disease prevention and control center of Inner Mongolia autonomous region, Hohhot, Inner Mongolia Autonomous Region, China

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: nab-paclitaxel

First Posted Date: 2019-12-11

Last Posted Date: 2019-12-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 108

Registration Number: NCT04194684

Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases

Not Applicable

Completed

Conditions: Brain Metastases

Interventions: Radiation: tomotherapy

First Posted Date: 2019-11-26

Last Posted Date: 2019-11-26

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 82

Registration Number: NCT04178330

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy